Sibel Health Secures $3.5 Million ARPA-H Contract to Develop First-in-Class Wearable Edema Monitor
核心洞察
Sibel Health (搜索) received a $3.5 million Direct-to-Phase II SBIR contract from ARPA-H (搜索) to develop an ambulatory edema (搜索) monitoring device that continuously tracks lower-leg swelling outside clinical settings.
The wearable biosensor aims to replace subjective manual edema (搜索) assessment with objective, continuous monitoring for conditions like congestive heart failure (搜索), which affects over 6 million Americans and costs the healthcare system $35 billion annually.
The ultra-thin, flexible sensor will integrate with Sibel's existing FDA-cleared mobile platform and represents a transformative investment in addressing a long-ignored clinical symptom.
Sibel Health (搜索), a Chicago-based medical technology company, has been awarded a $3.5 million Direct-to-Phase II Small Business Innovation Research (SBIR) contract from the Advanced Research Projects Agency for Health (ARPA-H (搜索)) to develop a first-in-class wearable device for continuous edema (搜索) monitoring. The ambulatory edema monitor represents a significant advancement in objective physiological monitoring, capable of tracking lower-leg edema outside traditional clinical examination rooms.
Addressing a Critical Gap in Clinical Assessment
Tissue edema (搜索)—the pathological accumulation of fluid—affects patients across multiple medical conditions, from breast cancer (搜索) to venous insufficiency (搜索). In congestive heart failure (搜索), a condition impacting more than 6 million Americans and generating over $35 billion annually in healthcare costs through hospitalizations and readmissions, lower leg swelling serves as an early indicator of clinical deterioration.
Despite the clinical significance of edema (搜索) monitoring, the standard assessment method has remained unchanged for decades. Current practice involves a clinician pressing a finger into the patient's skin for several seconds, releasing it, and grading the resulting indentation on a four-point scale. This subjective approach lacks the precision needed for optimal clinical decision-making.
ARPA-H (搜索) recognized the critical need for objective wearable technologies capable of accurately determining edema (搜索) status to influence clinical care. The Direct-to-Phase II award to Sibel Health (搜索) reflects what the agency describes as a "transformative, high-risk, high-reward investment" targeting a clinical symptom that has been historically underserved.
Innovative Multimodal Biosensor Technology
Sibel Health (搜索), which emerged from the research laboratory of Professor John Rogers and the Querrey Simpson Institute for Bioelectronics (搜索) at Northwestern University, will develop an ultra-thin, soft, and flexible wearable sensor capable of wirelessly assessing tissue fluid status. The proposed multi-modality biosensor patch aims to replace subjective manual assessment with continuous, objective monitoring.
The new sensor will integrate with Sibel's existing FDA-cleared mobile software platform and cloud infrastructure, creating a comprehensive monitoring ecosystem. According to the company, continuous ambulatory edema (搜索) monitoring requires addressing "deeply intertwined hardware, sensing, signal processing, and clinical challenges" that have prevented previous efforts from achieving commercial or clinical viability.
"ARPA-H (搜索) is making the kinds of investments in health research and development that the private sector alone will not make—especially when the technology risk is high and the unmet clinical needs have been underserved," said Steve Xu MD, CEO of Sibel Health (搜索) and Principal Investigator for the project. "We are deeply grateful to ARPA-H for selecting Sibel and our team to execute on this program."
Established Platform and Clinical Applications
Sibel Health (搜索)'s existing product portfolio demonstrates the company's expertise in wearable biosensor development. The FDA-cleared ANNE One™ wireless monitoring system provides continuous physiological monitoring for both pediatric and adult patients, while ANNE Maternal™ focuses on maternal fetal monitoring applications.
The company's mission centers on delivering "Better Health Data for All®" across diverse healthcare settings, from advanced academic medical centers to resource-limited environments worldwide. This new edema (搜索) monitoring technology represents an expansion of Sibel's continuous monitoring capabilities into a previously underserved clinical area.
The Direct-to-Phase II SBIR contract, funded under Award Number 140D0426C0027, enables Sibel Health (搜索) to bypass traditional Phase I development and proceed directly to advanced prototype development and testing. This accelerated pathway reflects ARPA-H (搜索)'s confidence in both the technology's potential and the company's execution capabilities.